Ftse Mib
33.844,95
0,00%
DAX
18.379,94
0,00%
S&P 500
5.537,02
0,51%
NASDAQ
18.188,30
0,88%
Bitcoin
58.750,73
-2,35%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Canada CSE Algernon Pharmaceuticals Inc (AGN) Algernon Pharmaceuticals Inc (AGN) Notizie

AGN

Algernon Pharmaceuticals (AGN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:CSE:AGN
DataOraFonteTitoloSimboloCompagnia
11/02/202114:00InvestorsHub NewsWireAlgernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study ProtocolCSE:AGNAlgernon Pharmaceuticals Inc
04/06/202018:41InvestorsHub NewsWireAlgernon Receives U.S. FDA Clearance for Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19CSE:AGNAlgernon Pharmaceuticals Inc
13/04/202015:44InvestorsHub NewsWireAlgernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) HowardCSE:AGNAlgernon Pharmaceuticals Inc
13/03/202013:40InvestorsHub NewsWireAlgernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and EmergencyCSE:AGNAlgernon Pharmaceuticals Inc
06/03/202014:32InvestorsHub NewsWireAlgernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for CoronavirusCSE:AGNAlgernon Pharmaceuticals Inc
31/07/201913:22InvestorsHub NewsWireAlgernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) ...CSE:AGNAlgernon Pharmaceuticals Inc
29/07/201914:32InvestorsHub NewsWireAlgernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis ...CSE:AGNAlgernon Pharmaceuticals Inc
03/07/201915:06InvestorsHub NewsWireAlgernon Pharmaceuticals' NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56%CSE:AGNAlgernon Pharmaceuticals Inc
04/06/201914:00InvestorsHub NewsWireQ&A with Christopher J. Moreau CEO of Algernon PharmaceuticalsCSE:AGNAlgernon Pharmaceuticals Inc
28/05/201914:00InvestorsHub NewsWireAlgernon Pharmaceuticals: Join us for an interview with the CEO and CSOCSE:AGNAlgernon Pharmaceuticals Inc
23/05/201914:04InvestorsHub NewsWireRepurposing Drugs Reduces Investment Risk. Algernon Pharma Plans Phase 2 Trials for NASH, CKD and IBDCSE:AGNAlgernon Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:CSE:AGN

La tua Cronologia

NASDAQ
ZAFHOX
Audax Private Equity Fun...
NASDAQ
ZABODX
Advanced Technology Vent...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network